Endogenous drug transporters in in vitro and in vivo models for the prediction of drug disposition in man

被引:133
作者
Goh, LB
Spears, KJ
Yao, DG
Ayrton, A
Morgan, P
Wolf, CR
Friedberg, T [1 ]
机构
[1] Univ Dundee, Ninewells Hosp & Med Sch, Ctr Biomed Res, Dundee DD1 9SY, Scotland
[2] GlaxoSmithKline, Welwyn Garden City AL6 9AR, Herts, England
[3] Pfizer Global Res, Sandwich CT13 9NJ, Kent, England
关键词
drug disposition; cell lines; recombinant models; expression profiling;
D O I
10.1016/S0006-2952(02)01355-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The epithelial canine and porcine kidney cell lines MDCK, MDCKII and LLC-PK1, respectively are employed to establish recombinant models of drug transport. Endogenous drug carriers in these cells may contribute to the activities of recombinant drug transporters, thus making it difficult to assess their properties. We analysed the expression of endogenous transporters in these cell lines by RT-PCR and by determining drug transporter activities. Concerning drug efflux, multidrug resistance protein 1 (MDR1) and MRP1 mRNAs were found in all lines. MRP2 mRNA was expressed in all cell lines except MDCK. Transepithelial transport of vinblastine and its modulation by a MDR1-specific inhibitor or by the MDR1- and MRP-inhibitor verapamil, indicated that MDCKII cells have, in comparisons to the other cell lines, relatively high levels of functional MDR1 while vinblastine transport in MDCK cells is likely to be mediated more by MRP1. Notably, LLC-PK1 cells displayed little activity attributable to either MDR1 and MRP1, thus making them suitable for the expression of these efflux pumps. Of the drug uptake carriers, OATP-A mRNA was only expressed in MDCK cells. OATP-C mRNA was barely detectable in MDCK cells and absent in MDCKII and LLC-PK1 cells. In agreement with transcriptional profiling, the OATP-mediated uptake of either estradiol-glucuronide or estrone-sulfate was either absent or barely detectable in all cell lines thus implying that they are suitable to establish recombinant models for human OATP's. Transcriptional profiling was also performed on porcine and canine tissues and revealed that MRP1 was expressed in canine but not in human or porcine liver, whereas surprisingly OATP-C was expressed in canine kidney but only in human and porcine liver. The findings presented are relevant to the use of porcine and canine models for drug disposition. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:1569 / 1578
页数:10
相关论文
共 31 条
[1]   Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1 [J].
Abe, T ;
Kakyo, M ;
Tokui, T ;
Nakagomi, R ;
Nishio, T ;
Nakai, D ;
Nomura, H ;
Unno, M ;
Suzuki, M ;
Naitoh, T ;
Matsuno, S ;
Yawo, H .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (24) :17159-17163
[2]   Role of transport proteins in drug absorption, distribution and excretion [J].
Ayrton, A ;
Morgan, P .
XENOBIOTICA, 2001, 31 (8-9) :469-497
[3]   A family of drug transporters: The multidrug resistance-associated proteins [J].
Borst, P ;
Evers, R ;
Kool, M ;
Wijnholds, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2000, 92 (16) :1295-1302
[4]  
CHEN CJ, 1990, J BIOL CHEM, V265, P506
[5]   Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter [J].
Chen, ZS ;
Kawabe, T ;
Ono, M ;
Aoki, S ;
Sumizawa, T ;
Furukawa, T ;
Uchiumi, T ;
Wada, M ;
Kuwano, M ;
Akiyama, S .
MOLECULAR PHARMACOLOGY, 1999, 56 (06) :1219-1228
[6]   Cloning of the full-length coding sequence of rat liver-specific organic anion transporter-1 (rlst-1) and a splice variant and partial characterization of the rat lst-1 gene [J].
Choudhuri, S ;
Ogura, K ;
Klaassen, CD .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2000, 274 (01) :79-86
[7]  
COLE SPC, 1994, CANCER RES, V54, P5902
[8]   Inter-species differences in drug properties [J].
Collins, JM .
CHEMICO-BIOLOGICAL INTERACTIONS, 2001, 134 (03) :237-242
[9]   Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1 [J].
Conrad, S ;
Viertelhaus, A ;
Orzechowski, A ;
Hoogstraate, J ;
Gjellan, K ;
Schrenk, D ;
Kauffmann, HM .
TOXICOLOGY, 2001, 156 (2-3) :81-91
[10]  
Cui YH, 1999, MOL PHARMACOL, V55, P929